Akouos is a genetic medicine company, engaged in developing gene therapies to restore, enhance, and preserve physiologic hearing for individuals who live with disabling hearing loss. Co. has a genetic medicine platform that incorporates a proprietary vector library consisting small virus used in gene therapy, known as adeno-associated virus, and a delivery approach. Co. is developing its primary product candidate, AK-OTOF; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities and a commercial infrastructure. The AKUS stock yearly return is shown above.
The yearly return on the AKUS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AKUS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|